Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection
Andrew G. Polson(Sunesis (United States)), Allen Ebens(Unknown), Bernd J. Wranik, Shang‐Fan Yu(Genesys (United States)), Dan Eaton(Enzo Life Sciences (United States)), Frédéric J. de Sauvage(Gene Therapy Laboratory), Gladys S. Ingle, Reina N. Fuji, Saileta Prabhu, Suzanna Clark, Bing Zheng, Susan D. Spencer, Erin Christensen, Hartmut Koeppen, Noelyn M. Kljavin, Jill Calemine-Fenaux, Kristi Elkins, Christopher A. Nelson, Jean-Philippe Stéphan, Sarajane Ross, J. Michael Elliott, Wesley Chang(California Institute of Technology), Gretchen Frantz, Suzie J. Scales(Unknown), Alane Gray, Kristin Harden, Richard Vandlen(PDL BioPharma (United States)), Pamela Chan, Helga Raab
Cited by 248
Related Papers
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
|Nature Immunology|2008|1.5k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
|Cancer Cell|2014|1.1k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
Recurrent R-spondin fusions in colon cancer
|Nature|2012|973